Volf V, Burgada R, Raymond K N, Durbin P W
National Institute of Public Health, Centre of Industrial Hygiene and Occupational Diseases, Praha, Czech Republic.
Int J Radiat Biol. 1996 Dec;70(6):765-72. doi: 10.1080/095530096144653.
The effectiveness of the siderophore analogues DFO-HOPO (a hydroxypyridone derivative of desferrioxamine) and 3,4,3-LIHOPO (a linear tetrahydroxypyridinone) for the decorporation of 238Pu and 241Am from rat was studied. (1) Dosage-effect relationship. A similar treatment effect on Pu was achieved by single s.c. injection of 30 mumol kg-1 or by oral administration of 100 mumol kg-1 of either of the two ligands, provided the oral dose was administered earlier. In general, LIHOPO was more effective than DFO-HOPO: retention of Pu in the liver and bones was reduced by LIHOPO to < 10% of control values. No increase in renal retention of the actinides was observed. Whilst DFO-HOPO did not affect Am retention, a substantial reduction was achieved by LIHOPO. Removal effectiveness for injected LIHOPO on Pu was higher than that on Am, especially in the bones and after low ligand doses. Orally administered small doses of LIHOPO, however, mobilized more Am than Pu, both from the liver and the bone. (2) Time-effect relationship. The effectiveness of the injected ligands for Pu decreased exponentially with the time between exposure and treatment. With DFO-HOPO, the calculated half-times for decrease of mobilized fractions of Pu from the bone and liver were 5 and 12 h respectively. The effect of LIHOPO on Pu decreased much more slowly, with a half-time of 3-4 weeks. For instance, a single injection of 30 mumol kg-1 LIHOPO at 10 days post-Pu removed 30 and 50% activity from the bone and liver respectively. The removal effect of LIHOPO for Am in the liver decreased with time in the same way as for Pu but the mobilized fractions of skeletal and renal Am decreased from the first day with a half-time of only 8 and 4 days respectively.
研究了铁载体类似物DFO - HOPO(去铁胺的羟基吡啶酮衍生物)和3,4,3 - LIHOPO(线性四羟基吡啶酮)对大鼠体内238Pu和241Am促排的效果。(1)剂量 - 效应关系。通过单次皮下注射30 μmol/kg或口服100 μmol/kg这两种配体中的任何一种,对Pu可获得相似的治疗效果,前提是口服剂量给药更早。一般来说,LIHOPO比DFO - HOPO更有效:LIHOPO可使肝脏和骨骼中Pu的滞留量降低至对照值的<10%。未观察到锕系元素在肾脏中的滞留增加。虽然DFO - HOPO不影响Am的滞留,但LIHOPO可使其大幅降低。注射LIHOPO对Pu的去除效果高于对Am的去除效果,尤其是在骨骼中以及低剂量配体时。然而,口服小剂量的LIHOPO从肝脏和骨骼中动员的Am比Pu更多。(2)时间 - 效应关系。注射的配体对Pu的有效性随暴露与治疗之间的时间呈指数下降。对于DFO - HOPO,计算得出骨骼和肝脏中Pu动员分数下降的半衰期分别为5小时和12小时。LIHOPO对Pu的作用下降得慢得多,半衰期为3 - 4周。例如,在注射Pu后10天单次注射30 μmol/kg的LIHOPO,分别从骨骼和肝脏中去除了30%和50%的活性。LIHOPO对肝脏中Am的去除效果与对Pu的去除效果随时间以相同方式下降,但骨骼和肾脏中Am的动员分数从第一天开始下降,半衰期分别仅为8天和4天。